Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Abstract Text:

Jonathan E Rosenberg,Vivian K Weinberg,W Kevin Kelly,Dror Michaelson,Maha H Hussain,George Wilding,Mitchell Gross,Douglass Hutcheon,Eric J Small,Jonathan E Rosenberg,Vivian K Weinberg,W Kevin Kelly,Dror Michaelson,Maha H Hussain,George Wilding,Mitchell Gross,Douglass Hutcheon,Eric J Small,

BACKGROUND: This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second-line chemotherapy for taxane-refractory, hormone-refractory, prostate cancer (HRPC). METHODS: Patients with HRPC that progressed during or within 60 days of cessation of taxane chemotherapy were randomly selected with equal probability to ixabepilone 35 mg/m(2) intravenously every 3 weeks, or mitoxantrone 14 mg/m(2) intravenously every 3 weeks and prednisone 5 mg orally twice daily. Treatment continued until progression or toxicity; crossover was allowed. RESULTS: Forty-one patients were accrued to each arm of the study. The median number of cycles administered for each arm was 3. Median survival from protocol entry was 10.4 months with ixabepilone and 9.8 months with MP. Prostate-specific antigen (PSA) declines of >or=50% were observed in 17% of ixabepilone (95% CI, 7-32) and 20% of second-line MP patients (95% CI, 9-35). Partial responses were observed in 1 of 24 ixabepilone and in 2 of 21 MP patients with evaluable measurable disease. Median duration of second-line ixabepilone and MP treatment was 2.2 months and 2.3 months, respectively. For third-line crossover treatment, PSA declines of >or=50% were observed in 3 of 27 ixabepilone-treated and 4 of 15 MP-treated patients. Prior taxane response was associated with an increased likelihood of second-line ixabepilone or MP response. Low baseline lactate dehydrogenase and absence of visceral metastases independently predicted improved survival. The most common grade 3/4 toxicity associated with second-line treatment was neutropenia (54% of ixabepilone patients and 63% of MP patients). CONCLUSIONS: Ixabepilone and MP had modest activity as second-line chemotherapy for docetaxel-refractory HRPC. The median survival for the entire cohort treated in this study was 9.8 months.

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Publishing Authors By Initials

JE Rosenberg,VK Weinberg,WK Kelly,D Michaelson,MH Hussain,G Wilding,M Gross,D Hutcheon,EJ Small,JE Rosenberg,VK Weinberg,WK Kelly,D Michaelson,MH Hussain,G Wilding,M Gross,D Hutcheon,EJ Small,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Cancer

VOLUME: 110

Page Numbers: 556-63

Journal Abbreviation: Cancer

ISSN: 0008-543X

DAY: 1

MONTH: Aug

YEAR: 2007

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 374236

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

AFFILIATION: Department of Medicine, University of California at San Francisco, Comprehensive Cancer Center, San Francisco, California, USA. jrosenbe@medicine.ucsf.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone Related Publications

• 281.
• Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
• Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
• An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus.
• Blank augmentation protocol for improving the robustness of multivariate calibrations.
• CA3 NMDA receptors are required for experience-dependent shifts in hippocampal activity.
• Cognitive deficits in preclinical Alzheimer's disease and vascular dementia: patterns of findings from the Kungsholmen Project.
• Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells.
• Globally distributed mycobacterial fish pathogens produce a novel plasmid-encoded toxic macrolide, mycolactone F.
• Hearing lips and seeing voices: how cortical areas supporting speech production mediate audiovisual speech perception.
• Imaging the earliest stages of Alzheimer's disease.
• Imaging-guided microarray: isolating molecular profiles that dissociate Alzheimer's disease from normal aging.
• Jagged-1hi or Delta-1hi thymic stromal cell populations can trigger acquisition of Thy-1 and loss of B220.
• Longitudinal mapping of mouse cerebral blood volume with MRI.
• Molecular evolution of the Li/li chemical defence polymorphism in white clover (Trifolium repens L.).
• Photoacoustic characterization of protein dynamics following CO photodetachment from fully reduced bovine cytochrome c oxidase.
• Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
• Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.
• Psychosocial functioning of adults who experienced substance use disorders as adolescents.
• Quantitative determination of ethanol in heated plumes by passive Fourier transform infrared remote sensing measurements.
• Repetition suppression for spoken sentences and the effect of task demands.
• Screening for depressive symptoms in patients with unresectable lung cancer.
• Selective expression of an aP2/Fatty Acid Binding Protein 4-Cre transgene in non-adipogenic tissues during embryonic development.
• Spectral simulation methodology for calibration transfer of near-infrared spectra.
• Speech-associated gestures, Broca's area, and the human mirror system.
• Task-dependent changes in brain activation following therapy for nonfluent aphasia: discussion of two individual cases.
• The mind of expert motor performance is cool and focused.
• Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.
• Trying to detect taste in a tasteless solution: modulation of early gustatory cortex by attention to taste.
• Using the COPE intervention for family caregivers to improve symptoms of hospice homecare patients: a clinical trial.